1 Title: Comparative Clinical Evaluation of the Alinity m STI Multiplex PCR Assay for 2 Diagnosis and Surveillance of Chlamydia trachomatis, Neisseria gonorrhea, 3 Trichomonas vaginalis, and Mycoplasma genitalium 4 Amorce Lima, PhD1*, Dominic Uy, MB1, Joshua Kostera, PhD2, Suzane Silbert, PhD1 5 6 ¹ Tampa General Hospital, Tampa, FL, USA 7 8 ² Abbott Laboratories, Des Plaines, IL, USA 9 10 *Corresponding author: Amorce Lima, PhD 11 Tampa General Hospital 12 1 Tampa General Circle 13 Tampa, FL 33606 USA 14 Phone: 813-660-6357 15 Email: alima@tgh.org 16 17 Word counts: summary 26; abstract 269; main text 3111 18 Number of references: 30 19 Number of figures: 5 20 Number of tables: 2 21 22 Conflicts of Interest and Source of Funding 23 Joshua Kostera is an employee of Abbott Laboratories. This study was funded by a 24 grant from Abbott Laboratories.

Summary

25

- 26 Evaluation of Alinity m STI clinical performance for diagnosis and surveillance of CT,
- NG, TV, and MG in a large academic medical center in the US.

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

Abstract Background: Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) are routinely tested and reported; however, Trichomonas vaginalis (TV) is the most common STI in the US and the prevalence of Mycoplasma genitalium (MG) infections is likely higher than estimated. We examined the clinical performance of the Alinity m STI assay for detection and surveillance of CT/NG/TV/MG in urine specimens from patients at a large academic medical center. **Methods:** Prevalence of mono- and co-infections on Alinity m STI pathogens and predictors of a positive result were identified. Alinity m STI and Aptima Combo 2 CT/NG and TV assay (Panther System) results were compared, with discrepant results run on the cobas 6800 CT/NG, TV and MG assays. Analyzer turnaround times (TAT) were determined for Alinity m and Panther systems. **Results:** 199 urine specimens were included. Age ≥25 years, collection outside the emergency department (ED), and asymptomatic status were predictive of TV or MG infection; symptomatic status was the only predictor of CT or NG infection. Overall agreement rates for the Alinity m, Aptima, and cobas assays ranged from 86.4% to 99.5% for the four pathogens. TV and MG infections comprised 54% of the positive samples and were more often asymptomatic than CT and NG infections. Analyzer TAT (onboard to result reporting) was 4 hours 45 minutes for the Aptima CT/NG, 3 hours 25 minutes for Aptima TV, and 1 hour 55 minutes for Alinity m STI assay. Conclusions: The Alinity m STI assay allows for fast and simultaneous detection of the four major STI pathogens, which can facilitate surveillance and provide accurate results to help clinicians diagnose for initiation of appropriate treatment.

Key words: surveillance, nucleic acid amplification test, screening, DNA

Introduction

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

The most recent CDC surveillance data indicates that 2.5 million STIs were reported in 2021, an increase of almost 3% from 2020 (1). The four most common STI pathogens are Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), Trichomonas vaginalis (TV), and Mycoplasma genitalium (MG). Of these, TV is the most common, with 1.2% prevalence among 2013-2014 NHANES participants (2); however, TV is not considered reportable by CDC (3, 4). Current guidelines recommend TV screening only in high-risk populations (3). As the majority of individuals with TV infection are asymptomatic, it can remain undiagnosed and untreated for years, leading to severe consequential health outcomes such as pelvic inflammatory disease, urethritis, and infertility. MG has emerged as an STI pathogen of concern with drug resistant MG placed on CDC's Watch List in 2019 (5). Yet MG is not classified as reportable by CDC; current guidelines recommended MG testing in only a small subset of patients with recurrent urethritis or cervicitis (3). Thus, the true prevalence of MG infection is not clear and is likely higher than expected (6). Untreated STIs have significant long-term health consequences and inflict a substantial economic medical burden (7). Additionally, NG, TV, and MG infections are associated with increased risk for acquiring or transmitting HIV (3, 4, 8). Timely diagnosis of STIs is essential to reduce transmission and initiate treatment (3), but diagnosis based on patient symptoms alone can be challenging. Co-infections by more than one pathogen can cause overlapping symptoms that confound both diagnosis and initiation of appropriate therapy. Inaccurate diagnosis leading to inappropriate or inconsistent treatment can lead to the emergence of multidrug resistant strains (9-11).

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

Guidelines recommend screening for the reportable pathogens, CT and NG, with nucleic acid amplification tests (NAATs) to help reduce transmission and guide treatment (12, 13). Similar NAAT-based surveillance programs for TV and MG would be expected to identify subclinical or asymptomatic infections, refine treatment algorithms, and reduce transmission rates (3, 14, 15). Because sequential testing for each pathogen can prolong the time to diagnosis and delay initiation of appropriate treatment, NAATs have been developed for simultaneous detection of multiple pathogens from a single specimen. The Alinity m STI assay (Abbott Laboratories, Des Plaines, IL, USA) is an in vitro multiplex RT-PCR assay that is designed for qualitative and simultaneous detection of CT, NG, MG, and TV in various urogenital and extragenital specimens. The objective of this study was to evaluate the Alinity m STI assay and compare the results with our standard of care (SOC) STI tests, the Aptima Combo 2 CT/NG and the Aptima TV assays, run on the Panther system (Hologic, Marlborough, MA) for urine specimens collected from patients at a large academic medical center in the United States. We also examined the utility of the Alinity m STI assay for surveillance of TV and MG infection. **Materials and Methods** Specimens and setting 199 residual de-identified urine specimens from consecutive inpatients, outpatients, and patients in the emergency department (ED) at Tampa General Hospital (TGH; Tampa, Florida, USA) were included in the study after SOC testing. No inclusion or

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

exclusion criteria were applied. The study was conducted following GCLP and in accordance with the Declaration of Helsinki, under IRB# 1301043. Specimen collection and disposition Approximately 2 mL of first catch urine specimen was transferred from the primary urine collection container to an Aptima Urine Specimen Transport Tube for SOC testing on the Panther system (Figure 1). Two additional 5-mL aliquots from the primary urine collection container were pipetted into cryogenic vials: Aliquot #1 was transferred to the Alinity m multi-collect tube which was used for testing on the Alinity m STI assay and Aliquot #2 was used for referral testing to confirm MG positives on Alinity m and resolve any discrepant results. All MG-positive specimens and at least 5 MG-negative specimens on Alinity m STI with sufficient remaining volume were sent to the University of Alabama STD Diagnostics Lab (UAB; Birmingham, AL, USA), to be tested for CT, NG, TV, and MG on the cobas 6800 system (Roche, Branchburg, NH, USA). All specimens with discrepant results on the Aptima and Alinity m assays with sufficient volume for Aliquot #2 were also sent to UAB for testing with the cobas 6800 CT/NG, TV and MG assays. Assay platforms The Alinity m STI assay (Abbott Laboratories) was run on a single Alinity m analyzer at TGH according to the manufacturer's instructions using reagents that was not yet approved by the FDA for that purpose. The Alinity m STI assay primers and probes amplify and detect an endogenous human DNA sequence as validity control (cellular

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

control, CC) and an exogenous internal control (IC) is used to confirm the absence of PCR inhibitors in the test specimen. For this study, 2.1 mL of each collected urine specimen was transferred from Aliquot #1 to an Alinity m multi-Collect tube for testing and the analyzer was programmed to test all four STI pathogens (CT, NG, MG, and TV). Alinity m reagents were left onboard the analyzer for 10-30 days. The Aptima Combo 2 for CT/NG and Aptima TV assays were run on the Panther system (Hologic, Inc.) at TGH. If clinical orders were for CT/NG testing only, then TV testing was performed using the same specimen. Because onboard stability of the Aptima reagents is 72 hours, TV testing was performed in batches. Upon completion of testing, the reagents were removed from the Panther instrument and refrigerated. If TV testing was not done on the same day as CT/NG testing, specimens were stored at 2-8°C until the next batch run. The cobas 6800 CT/NG assay and cobas 6800 TV/MG assays were run at UAB. All assays were run following the manufacturers' instructions. Workflow study Total TAT for the Alinity m STI assay were calculated based on timepoints entered into the laboratory information system and electronic medical record. The average time from specimen receipt to results reporting and from specimen loading onto the analyzer to results reporting were tracked. Data analysis The prevalence of each analyte and co-infections in the study population were

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

determined based on the Alinity m STI assay results. Positive, negative, and overall percent agreement (PPA, NPA, OPA) and 95% confidence intervals (CIs) and kappa values were determined for results from the Alinity m STI assay and the comparator assays. Odds ratios and 95% Cls were calculated to identify variables predictive of positive Alinity m STI assay results. Results Study cohort characteristics and test results Urine specimens from 199 patients were included in the study; demographic characteristics are shown in Table 1. The majority of specimens were collected from females and in the inpatient setting. Median patient age was 29 years; of note, a patient between the age of 6-10 was included, but was the only patient under 16 years of age and was negative for all pathogens tested on the Aptima CT/NG and TV assays and Alinity m STI assay (CT/NG/TV/MG). The cohort was diverse, with slightly more Black patients than White or Hispanic patients. Eighteen patients in the "Other" category were Asian, mixed-race, Middle Eastern, or chose not to identify their racial/ethnic background. Forty-three patients had positive Alinity m assay results (Table 1). There were 7 CT, 4 NG, 12 TV, and 11 MG mono-infections; 3 CT/NG co-infections; 3 CT/MG coinfections; 2 NG/TV co-infections; and 1 TV/MG co-infection. No triple or quadruple co-infections were detected. TV and MG infections comprised more than half (54%) of the positive samples and 14% were co-infections with CT or NG (Figure 2A). Only 25% of positive results were CT or NG mono-infections and 7% were CT/NG coinfections. The mean age of patients with TV or MG mono-infections or TV/MG co-

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

infection was 32 years, 5 years older than the mean age of patients with CT or NG mono-infection or CT/NG co-infection. In this cohort, TV, MG, TV/MG, and associated co-infections were mostly asymptomatic (20 asymptomatic and 9 symptomatic), whereas CT, NG, CT/NG infections were more often symptomatic (10 symptomatic and 4 asymptomatic). The distribution of Alinity m STI positive results varied based on site of specimen collection (Figure 2B). The vast majority of positive specimens collected in the inpatient setting were from asymptomatic patients, whereas the majority of positive specimens collected in the ED and all positive specimens collected in the outpatient setting were from symptomatic patients. Specimens were tested on 82 unique testing days over the course of 10 months. Predictors of positive Alinity m STI assay results Factors that were most predictive of an assay result positive for TV or MG mono- or co-infection were age ≥25 years, specimen collected at a site outside the ED, and asymptomatic status (Figure 3A). The only factor predictive of CT, NG, or CT/NG positive results was symptomatic status (Figure 3B). Specimen collection outside the ED was somewhat predictive of a positive CT, NG, or CT/NG result. Comparative performance of STI NAATs Agreement between Alinity m STI, Aptima CT/NG, Aptima TV, and cobas MG assay results is summarized in Table 2. Overall percent agreement (OPA) between Alinity m STI and comparator assay results was 99.5% (95%CI: 97.2%, 99.9%) for CT, 99.5% (95%CI: 97.2%, 99.9%) for NG, 98.4% (95%CI: 95.5%, 99.5%) for TV, and 86.4% (95%CI: 66.7%, 95.3%) for MG.

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

For CT, 1 specimen collected from an asymptomatic female patient in her 20s was CT-positive on Aptima, CT-negative on Alinity m, and CT-positive on cobas. The review of the Aptima CT/NG relative light units (RLU) for this specimen was 829 vs mean RLU for all CT-positive specimens was 1125 (SD 227), indicating a low CT concentration in the specimen that was not detected by Alinity m STI. One specimen collected from an asymptomatic female patient under 20 years old was NG-positive on Aptima and NG-negative on Alinity m. The RLU on Aptima CT/NG for this specimen was 563, more than 3 SD from the mean RLU for all NGpositive specimens of 1299 (SD 154). The specimen was also found to be NGnegative on cobas, in agreement with the Alinity m STI result. Two specimens were found to be TV-positive on Aptima and TV-negative on Alinity m STI assay. The first was from an asymptomatic male patient in his 50s that was TV-negative on cobas. The specimen was not positive for any other pathogen. The specimen RLU on Aptima TV was 133, more than 2 SD from the mean RLU of 1324 (SD 369) for all TV-positive specimens from asymptomatic patients. The second specimen, from an asymptomatic female patient in her early 40s, was TV-positive on cobas. The TV RLU was 1528, within 1 SD of the mean RLU of 1324. One specimen from an asymptomatic female in her 30s was TV-negative on Aptima, TV-positive on Alinity m, and TV-negative on cobas. Three specimens were MG-negative on cobas but MG-positive on Alinity m. One specimen from a symptomatic female patient and another from an asymptomatic female patient in their 20s were negative for CT/NG/TV on Alinity m, negative for

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

CT/NG and TV on Aptima, and negative for CT/NG and TV/MG on cobas. The third specimen, from an asymptomatic female patient in her 30s, was also TV-positive on the Alinity m, Aptima, and cobas assays. The cause for the discrepancy between Alinity m and cobas MG results could potentially be attributable to neat sample degradation between collection and testing with cobas or assay sample type sensitivities. For the 8 specimens with discrepant results on the Aptima, Alinity m, and cobas assays, there was no significant difference in the Alinity m IC and CC cycle number (CN) values compared to the average IC and CC CN values of all specimens in cohort (see Table, Supplemental Digital Content 1). Aptima and Alinity m STI assay performance by symptom status Although the assays are qualitative, we compared assay readouts (RLU for Aptima and CN for Alinity m) across target pathogens and in specimens from symptomatic and asymptomatic patients. Aptima RLUs were significantly higher for specimens from symptomatic patients with CT/NG co-infection compared to those with CT, NG, or TV mono-infection or in asymptomatic patients (Figure 4A). It is not surprising that higher RLUs were seen with co-infections, as they would elicit a double probe response. CN values for specimens run on the Alinity m STI assay were consistently between 10 and 40 and did not differ by symptom status (Figure 4B). Aptima and Alinity m STI workflow analysis

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

We compared the workflows for each assay for 199 specimens. The average overall turnaround time, from receipt of the specimen in the lab to results reporting, for the Alinity m STI assay for all four analytes was 6 hours 59 minutes (n=199; Figure 5A). The overall turnaround time was 8 hours 28 minutes (n=199) for the Aptima CT/NG assay and 80 hours 56 minutes (n=128) for the Aptima TV assay, reflecting the batching of specimens. To assess workflow independent of batching, we examined the turnaround time from loading the specimen on the analyzer to results reporting for the three assays (Figure 5B). The average time from onboarding to result was 3 hours 25 minutes for the Aptima CT/NG assay, 3 hours 25 minutes for the Aptima TV assay, and 1 hour 55 minutes for the Alinity m STI assay for CT/NG/TV/MG. Discussion In this study, we found high agreement rates between the Alinity m STI assay and the Aptima Combo 2 and TV assays for CT/NG and TV (OPA ≥98.4%) or cobas TV/MG assay for MG (OPA=86.4%). Discrepant specimens that were negative on Alinity m were primarily seen in asymptomatic patients where a CN value was not generated or had high CN values greater than the assay cutoff cycle, indicating low levels of the pathogen target. These findings are consistent with a previous study demonstrating concordance of results from the Alinity m STI assay and RealTime CT/NG/TV assay run on the m2000 system (16). The prevalences of infection and co-infection in our study indicate that TV and MG infections are likely being missed. Only 2 out of the 14 positive TV samples had a microscopy test performed and both were negative. Current practice at our institution

is consistent with CDC guidance for CT and NG screening (3), with specimens run

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

on the Aptima CT/NG assay as the SOC test. We do not routinely test for TV, unless ordered by the provider and do not test for MG. In our cohort, 68% of positive samples on Alinity m were TV or MG positive (53% mono-infection) and were more likely to be from asymptomatic patients. Our findings are consistent with the literature that most TV/MG infections are asymptomatic. The Swiss STAR trial screened high-risk women and found a prevalence of undiagnosed TV up to 10.4% and MG up to 6.7% (17). A US study of 374 female adolescents in juvenile detention found that 8% tested positive for TV and half of these were asymptomatic (18). Another study of men who have sex with men (MSM) with HIV who were screened for MG found a 20% prevalence, 93% of which were asymptomatic (19). Addition of TV and MG testing would reduce the likelihood of missed infections, decrease the risk of transmission, and improve appropriate antimicrobial use. Identification of factors predictive of positive TV and MG results on Alinity m STI or other NAATs could help inform adjustments to STI screening algorithms (1, 3) to ensure that asymptomatic infections are detected and treated. In our study, the mean age of patients with TV/MG-positive results was 5 years older than those with CT/NG-positive results. This is consistent with several surveillance studies showing that TV/MG infections are more likely to be diagnosed at a later age than CT/NG infections (3, 20-22). A recent US study of NHANES data found that women, smokers, non-Hispanic Black patients, and patients of lower socioeconomic status are more likely to have a TV infection (23). In contrast to our findings, a study of a high-risk population of women in New Mexico found that MG infection was more

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

prevalent in younger than older women (24). Rigorous, nationwide studies of predictors of MG infection are needed to develop evidence-based recommendations for MG testing. The distribution of positive Alinity m results by collection site illustrated that the ED is utilized to confirm infection in symptomatic patients. Studies suggest that a growing number of STIs are being diagnosed in the ED setting, possibly related to closure of STI clinics and increased utilization of the ED for primary care (25, 26). STI testing in the ED may help identify individuals with asymptomatic infection, allowing earlier initiation of treatment to stop transmission chains. A recent study developed a prediction model for identifying patients as candidates for CT/NG/TV testing in the ED, based on age, marital status, race, findings from vaginal wet prep, and urinalysis (27).In the workflow analysis, Alinity m STI reduced turnaround times compared to Aptima by removing the need for batching of TV assays. Simultaneous testing of all four pathogens also decreased the onboard to result turnaround times. Our findings are consistent with a previous report of faster turnaround times with the Alinity m STI assay compared to the Abbott RealTime assay run on the m2000 instrument (28). A workflow study of the Alinity m platform also demonstrated reduced the time to diagnosis and treatment initiation (29). More rapid results reporting has implications for management of STIs in the ED setting. A recent study suggested that rapid NAAT for STIs may help direct appropriate utilization of antimicrobials in the ED and reduce the risk of treatment resistance (30).

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

This was a single-center study, which may limit the generalizability of our findings; however, we utilized a third assay system run at a separate facility to resolve discrepancies in assay results. The Aptima system was not used to test for MG, which prevented a direct comparison to the Alinity m STI assay. This study also only utilized urine specimens; additional studies are needed to evaluate the performance of the Alinity m STI assay with other genital and extragenital specimen types and collection methods. Despite these limitations, this study utilized a convenience sample with no inclusion or exclusion criteria, which led to a diverse study cohort. We collected specimens from multiple sites in the medical center, and tested throughout the year to ensure that the sample was not enriched for certain peak periods. Our findings support the surveillance of MG and TV, which often remain as asymptomatic infections that serve as ongoing transmission reservoirs. Symptoms alone are non-diagnostic and can overlap significantly between CT, NG, TV, and MG. The Alinity m STI assay allows for simultaneous detection of the four major STI pathogens in a single assay, which can simplify the implementation of MG/TV surveillance programs in health systems that already report NG and CT infections. TV and MG surveillance programs can inform evidence-driven changes in the STI diagnostic algorithm, with multiplex assays moving patients more quickly to diagnosis and initiation of the most appropriate treatment. Acknowledgements The authors would like to thank Yan Zhang, PhD, for assistance with the statistical

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

analysis. Stacey Tobin, PhD, provided editorial support for manuscript preparation, with compensation from Abbott Laboratories. References 1. Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance 2021. 2023; Accessed at https://www.cdc.gov/std/statistics/2021/default.htm. Accessed May 23 2023. 2. Patel EU, Gaydos CA, Packman ZR, Quinn TC, Tobian AAR. Prevalence and Correlates of Trichomonas vaginalis Infection Among Men and Women in the United States. Clin Infect Dis. 2018;67(2):211-7. 3. Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep. 2021;70(4):1-187. 4. Muzny CA. Why Does Trichomonas vaginalis Continue to be a "Neglected" Sexually Transmitted Infection? Clin Infect Dis. 2018;67(2):218-20. 5. Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the United States 2019. Atlanta, GA: US Department of Health and Human Services; 2019; Accessed at https://www.cdc.gov/drugresistance/pdf/threats-report/2019-arthreats-report-508.pdf. Accessed August 28 2023. 6. Manhart LE, Holmes KK, Hughes JP, Houston LS, Totten PA. Mycoplasma genitalium among young adults in the United States: an emerging sexually transmitted infection. Am J Public Health. 2007;97(6):1118-25. 7. Chesson HW, Spicknall IH, Bingham A, et al. The estimated direct lifetime medical costs of sexually transmitted infections acquired in the United States in 2018. Sex Transm Dis. 2021;48(4):215-21. 8. Kissinger P, Adamski A. Trichomoniasis and HIV interactions: a review. Sex Transm Infect. 2013;89(6):426-33.

379	9.	Sethi S, Zaman K, Jain N. Mycoplasma genitalium infections: current treatment
380		options and resistance issues. Infect Drug Resist. 2017;10:283-92.

- 381 10. Getman D, Jiang A, O'Donnell M, Cohen S. Mycoplasma genitalium Prevalence,
- 382 Coinfection, and Macrolide Antibiotic Resistance Frequency in a Multicenter Clinical
- 383 Study Cohort in the United States. J Clin Microbiol. 2016;54(9):2278-83.
- 384 11. Unemo M, Jensen JS. Antimicrobial-resistant sexually transmitted infections:
- 385 gonorrhoea and Mycoplasma genitalium. Nat Rev Urol. 2017;14(3):139-52.
- 386 12. Recommendations for the laboratory-based detection of Chlamydia trachomatis and
- Neisseria gonorrhoeae--2014. MMWR Recomm Rep. 2014;63(Rr-02):1-19.
- 388 13. Nelson HD, Zakher B, Cantor A, Deagas M, Pappas M. Screening for Gonorrhea and
- Chlamydia: Systematic Review to Update the U.S. Preventive Services Task Force
- Recommendations. Rockville (MD); 2014.
- 391 14. Muzny CA, Burkholder GA, Fry KR, Austin EL, Schwebke JR. Trichomonas vaginalis
- 392 Nucleic Acid Amplification Testing at an Urban HIV Clinic. Sex Transm Dis.
- 393 2016;43(8):483-8.
- 394 15. Muzny CA, Blackburn RJ, Sinsky RJ, Austin EL, Schwebke JR. Added benefit of
- 395 nucleic acid amplification testing for the diagnosis of Trichomonas vaginalis among
- men and women attending a sexually transmitted diseases clinic. Clin Infect Dis.
- 397 2014;59(6):834-41.
- 398 16. Herrmann B, Malm K. Comparison between Abbott m2000 RealTime and Alinity m
- 399 STI systems for detection of Chlamydia trachomatis, Neisseria gonorrhoeae, and
- 400 Mycoplasma genitalium. Eur J Clin Microbiol Infect Dis. 2021.
- 401 17. Vernazza PL, Rasi M, Ritzler M, et al. The Swiss STAR trial an evaluation of target
- groups for sexually transmitted infection screening in the sub-sample of women.
- 403 Swiss Med Wkly. 2020;150:w20393.
- 404 18. Oshin E, Eissa MA, Benjamins LJ, Barratt MS, Beyda RM. Trichomonas Vaginalis
- 405 Infections Among Youth in Detention in the Southeastern United States. J Pediatr
- 406 Adolesc Gynecol. 2022;35(3):368-70.

407 19. Ring A, Balakrishna S, Imkamp F, et al. High Rates of Asymptomatic Mycoplasma 408 genitalium Infections With High Proportion of Genotypic Resistance to First-Line 409 Macrolide Treatment Among Men Who Have Sex With Men Enrolled in the Zurich 410 Primary HIV Infection Study. Open Forum Infect Dis. 2022;9(6):ofac217. 411 20. Flagg EW, Meites E, Phillips C, Papp J, Torrone EA. Prevalence of Trichomonas 412 vaginalis Among Civilian, Noninstitutionalized Male and Female Population Aged 14 413 to 59 Years: United States, 2013 to 2016. Sexually Transmitted Diseases. 414 2019;46(10). 415 21. Peterman TA, Tian LH, Metcalf CA, Malotte CK, Paul SM, Douglas JM, Jr. Persistent, 416 undetected Trichomonas vaginalis infections? Clin Infect Dis. 2009;48(2):259-60. 417 22. Sutton M, Sternberg M, Koumans EH, McQuillan G, Berman S, Markowitz L. The 418 prevalence of Trichomonas vaginalis infection among reproductive-age women in the 419 United States, 2001-2004. Clin Infect Dis. 2007;45(10):1319-26. 420 23. Tompkins EL, Beltran TA, Gelner EJ, Farmer AR. Prevalence and risk factors for 421 Trichomonas vaginalis infection among adults in the U.S., 2013-2014. PLoS One. 422 2020;15(6):e0234704. 423 24. Hammer A, Gravitt PE, Adcock R, Patterson N, Cuzick J, Wheeler CM. Burden of 424 Mycoplasma genitalium and Bacterial Coinfections in a Population-Based Sample in 425 New Mexico. Sex Transm Dis. 2021;48(12):e186-e9. 426 25. Hilbert SM, Reno HEL. Management of Patients with Sexually Transmitted Infections 427 in the Emergency Department. Emergency Medicine Clinics of North America. 428 2018;36(4):767-76. 429 26. Pearson WS, Peterman TA, Gift TL. An increase in sexually transmitted infections 430 seen in US emergency departments. Preventive Medicine. 2017;100:143-4. 431 27. Sheele JM, Niforatos JD, Elkins JM, Campos SC, Thompson CL. Prediction model 432 for gonorrhea, chlamydia, and trichomoniasis in the emergency department. Am J 433 Emerg Med. 2022;51:313-9.

437

438

439

441

444

445

446

28. Galindo LT, Hristov AD, Gentil LG, Scarpelli L, Santiago J, Levi JE. Performance 435 evaluation of the fully automated molecular system Alinity m in a high-throughput 436 central laboratory. J Clin Virol. 2021;137:104786. 29. Obermeier M, Pacenti M, Ehret R, et al. Improved molecular laboratory productivity by consolidation of testing on the new random-access analyzer Alinity m. Journal of Laboratory Medicine. 2020;44(6):319-28. 440 30. Rivard KR, Dumkow LE, Draper HM, Brandt KL, Whalen DW, Egwuatu NE. Impact of rapid diagnostic testing for chlamydia and gonorrhea on appropriate antimicrobial 442 utilization in the emergency department. Diagnostic Microbiology and Infectious 443 Disease. 2017;87(2):175-9.

447 Figure Legends 448 449 Figure 1. Study design. 450 451 Figure 2. Alinity m STI assay positive specimens in the study cohort. (A) Distribution 452 by mono-infection or co-infection. (B) Number of positive specimens collected in 453 each setting from asymptomatic or symptomatic patients. 454 455 Figure 3. Factors predictive of an Alinity m STI assay positive result. Odds ratios 456 and 95% confidence intervals for factors predicting (A) a positive TV, MG, TV/MG, 457 TV/NG, or MG/CT result or (B) a postive CT, NG, or CT/NG result on the Alintiy m 458 STI assay. 459 460 Figure 4. (A) Aptima Combo 2 RLU values and (B) Alinity m STI assay CN values 461 for positive specimens from symptomatic and asymptomatic patients. 462 463 Figure 5. Turnaround times for Alinity m STI assay on the Alinity m platform 464 compared to Aptima CT/NG and TV assays run on the Panther platform. (A) Overall 465 turnaround from specimen arrival in the lab to results reporting. (B) Onboard 466 turnaround from specimen loading on the analyzer to results reporting. 467 468 469

470 Tables

471

472

Table 1. Study Cohort Demographics

	Full Cohort (N=199) n (%)	Cohort with Positive Alinity m STI Assay Results (N=43) n (%)
Collection site		
Inpatient	112 (56.3)	21 (48.8)
Emergency department	35 (17.6)	14 (32.6)
Outpatient	31 (15.6)	3 (7.0)
Labor & Delivery	16 (8.0)	4 (9.3)
Other	5 (2.5)	1 (2.3)
Sex		
Female	145 (72.9)	28 (65.1)
Male	54 (27.1)	15 (34.9)
Age (y), median (range)	29 (9-74)	27 (16-63)
Race/ethnicity		
Black	73 (36.7)	22 (51.2)
Hispanic	58 (29.1)	10 (23.3)
White	50 (25.1)	9 (20.9)
Other	18 (9.1)	2 (4.6)
Symptom status ^a		
Asymptomatic	151 (76.0)	24 (55.8)
Symptomatic	45 (22.5)	19 (44.2)
Unknown	3 (1.5)	0 (0.0)

^a Symptom status data was available for n=199 of the full cohort and for all patients with positive Alinity m STI assay results.

Table 2. Agreement Between Alinity m STI Assay (CT/NG/TV/MG) and Aptima Combo 2 & Trichomonas vaginalis Assays (CT/NG and TV) or Cobas TV/MG Assay (MG) Results

			Cobas						
		СТ		NG		TV		MG	
Alinity m		POS	NEG	POS	NEG	POS	NEG	POS	NEG
	POS	13	0	9	0	14	1	10	3
	NEG	1	185	1	190	2	176	0	9
Agreement (95% CI)		OPA: 99.5% (PPA: 92.9% (NPA: 100.0%		OPA: 99.5% (97.2, 99.9%) PPA: 94.4% (59.6, 98.2%) NPA: 100.0% (98.0, 100.0%)		OPA: 98.4% (95.5, 99.5%) PPA: 87.5% (64.0, 96.5%) NPA: 99.4% (96.9, 99.9%)		OPA: 86.4% (66.7, 95.3) PPA: 100.0% (72.2, 100.0) NPA: 75.0% (46.8, 91.1)	

477 List of Supplemental Digital Content

478

479


480

Supplemental Digital Content 1.pdf

481 Figures


482 **Figure 1**

483




484 **Figure 2** 485

Α




В

486 487











В









Figure 5



В

